Key result
RHEIA trial tests non-inferiority of transfemoral TAVR versus SAVR in women with severe aortic stenosis.
Why the study?
Limited data suggest TAVR may be more effective than SAVR in female patients, but evidence is mostly from subgroup analyses and a dedicated randomized trial in women was lacking.
Is transfemoral TAVR non-inferior or superior to SAVR in reducing the 1-year composite of all-cause mortality, all stroke, or re-hospitalization in women with severe symptomatic aortic stenosis irrespective of surgical risk?
RCT (n=440)
Open-label (interventionalists and clinical events committee unblinded)
1:1 central electronic randomization
Yes
Is transfemoral TAVR non-inferior or superior to SAVR in reducing the 1-year composite of all-cause mortality, all stroke, or re-hospitalization in women with severe symptomatic aortic stenosis irrespective of surgical risk?
The RHEIA trial is the first dedicated randomized controlled trial designed to generate prospective evidence comparing the safety and efficacy of TAVR versus SAVR specifically in women with severe symptomatic aortic stenosis across all surgical risk profiles.
Answers are grounded in this paper and cite their sources.
First dedicated RCT of TAVR vs SAVR in women with severe AS; extends mixed-sex trial data to this population across risk strata.
BACKGROUND: Limited data suggest that transcatheter (TAVR) as compared with surgical aortic valve replacement (SAVR) may be more effective in female than male patients. To date, most evidence is derived from subgroup analyses of large trials, and a dedicated randomized trial evaluating whether there is a difference in outcomes between these interventions in women is warranted. The RHEIA trial will compare the safety and efficacy of TAVR with SAVR in women with severe symptomatic aortic stenosis requiring aortic valve intervention, irrespective of surgical risk. METHODS/DESIGN: The RHEIA trial is a prospective, randomized, controlled study that will enroll up to 440 patients across 35 sites in Europe. Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status, will be randomized 1:1 to undergo aortic valve intervention with either transfemoral TAVR with the SAPIEN 3 or SAPIEN 3 Ultra device or SAVR and followed up for 1 year. The objective is to determine whether TAVR is non-inferior to SAVR in this patient population and, if this is fulfilled whether TAVR is actually superior to SAVR. The primary safety/efficacy endpoint is a composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure) at 1 year post-procedure. Other outcomes (assessed at 30 days and/or 1 year) include all-cause mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular function; cognitive function, health status, and quality of life. DISCUSSION: The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk. The results will be the first to provide specific randomized evidence to guide treatment selection in female patients with severe symptomatic aortic stenosis. TRIAL REGISTRATION: clinicaltrials.gov: NCT04160130.
No takes yet. Share an insight, caveat, or question.
Eltchaninoff et al. (2020) conducted an RCT in Severe symptomatic aortic stenosis (n=440). Transfemoral transcatheter aortic valve replacement (TAVR) with SAPIEN 3 or SAPIEN 3 Ultra device vs. Conventional surgical aortic valve replacement (SAVR) using a commercially available surgical valve was evaluated on Composite of all-cause mortality, all stroke (disabling and non-disabling), and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure) at 1 year post-procedure.
Synapse has enriched 10 related papers. Consider them for comparative context: